ERBB2 and breast carcinoma: Although the results of the TRYPHAENA trial were published in 2013 [33], we were unable to use a HER2 blockade in our current neoadjuvant setting and study period because of the reimbursement policy of the Korean National Health Insurance system for locally advanced breast cancer.